Heartflow will present at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its AI technology for coronary artery disease.
Quiver AI Summary
Heartflow, Inc., a leader in AI technology for coronary artery disease, announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation can be accessed live and in archived form on Heartflow's Investor Relations website. Heartflow's innovative technology is enhancing precision cardiovascular care with AI and a comprehensive coronary imaging dataset, having been adopted by over 1,400 institutions worldwide. The company’s solutions, supported by extensive research and clinical validation, enable clinicians to deliver accurate, real-time analyses of coronary artery conditions, facilitating timely decision-making in patient care. Heartflow's platform also complies with high standards of data integrity and security, aiming to revolutionize the diagnosis and management of coronary artery disease.
Potential Positives
- Heartflow is presenting at the prestigious 44th Annual J.P. Morgan Healthcare Conference, showcasing its leadership in AI technology for coronary artery disease.
- The company has a strong market presence, having been adopted by over 1,400 institutions globally, which highlights its credibility and recognition in the healthcare sector.
- Heartflow's technology is backed by guidelines from respected organizations like the American College of Cardiology and the American Heart Association, reinforcing its clinical value.
- Heartflow's AI-driven solutions have been validated in over 100 studies assessing more than 365,000 patients, demonstrating their effectiveness and reliability in real-world applications.
Potential Negatives
- None
FAQ
When is Heartflow's presentation at the J.P. Morgan Healthcare Conference?
Heartflow's presentation will be on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
How can I access the presentation online?
A live and archived version of the presentation will be available on the Investor Relations section of the Heartflow website.
What technology does Heartflow use for coronary artery disease?
Heartflow uses AI technology and the world's largest coronary imaging dataset to redefine precision cardiovascular care.
How many patients have benefited from Heartflow's solutions?
Heartflow's AI-driven solutions have supported the care of over 500,000 patients worldwide.
What compliance standards does Heartflow meet?
Heartflow complies with international standards including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001 for data integrity and security.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HTFL Insider Trading Activity
$HTFL insiders have traded $HTFL stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HTFL stock by insiders over the last 6 months:
- JEFFREY C LIGHTCAP purchased 40,000 shares for an estimated $1,053,680
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HTFL Hedge Fund Activity
We have seen 84 institutional investors add shares of $HTFL stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 12,448,158 shares (+inf%) to their portfolio in Q3 2025, for an estimated $419,004,998
- WELLINGTON MANAGEMENT GROUP LLP added 4,880,064 shares (+inf%) to their portfolio in Q3 2025, for an estimated $164,262,954
- FMR LLC added 4,730,234 shares (+inf%) to their portfolio in Q3 2025, for an estimated $159,219,676
- BAILLIE GIFFORD & CO added 3,005,998 shares (+inf%) to their portfolio in Q3 2025, for an estimated $101,181,892
- SCHUSTERMAN INTERESTS, LLC added 1,939,201 shares (+inf%) to their portfolio in Q3 2025, for an estimated $65,273,505
- VANGUARD GROUP INC added 1,451,913 shares (+inf%) to their portfolio in Q3 2025, for an estimated $48,871,391
- CAPITAL INTERNATIONAL INVESTORS added 1,297,423 shares (+inf%) to their portfolio in Q3 2025, for an estimated $43,671,258
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HTFL Analyst Ratings
Wall Street analysts have issued reports on $HTFL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 11/13/2025
- JP Morgan issued a "Overweight" rating on 11/13/2025
- Canaccord Genuity issued a "Buy" rating on 11/13/2025
- Piper Sandler issued a "Overweight" rating on 09/02/2025
To track analyst ratings and price targets for $HTFL, check out Quiver Quantitative's $HTFL forecast page.
$HTFL Price Targets
Multiple analysts have issued price targets for $HTFL recently. We have seen 4 analysts offer price targets for $HTFL in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Robbie Marcus from JP Morgan set a target price of $40.0 on 11/13/2025
- William Plovanic from Canaccord Genuity set a target price of $40.0 on 11/13/2025
- Rick Wise from Stifel set a target price of $40.0 on 11/13/2025
- Matt OBrien from Piper Sandler set a target price of $38.0 on 09/02/2025
Full Release
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44 th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived version of the presentation will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com .
About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide.
1
Key benefits include:
- Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
- Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 97%.
- Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
-
Quality system, global security and patient-data integrity compliance:
Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.
About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The
Heartflow One
platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at
heartflow.com
.
Investor Contact
Nick Laudico
[email protected]
Media Contact
Elliot Levy
[email protected]
____________________
1
Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.
